ストックスクリーナーアプリを入手
67.96
5.87%
3.77
前日終値:
$64.19
開ける：
$64.5
24時間の取引高:
2.08M
Relative Volume:
1.73
時価総額：
$5.56B
収益：
-
当期純損益:
$-153.72M
株価収益率:
-33.98
EPS:
-2
ネットキャッシュフロー:
$-103.81M
1週間 パフォーマンス:
+5.84%
1か月 パフォーマンス:
+27.03%
6か月 パフォーマンス:
+142.80%
1年 パフォーマンス:
+309.64%
1日の値動き範囲:
$64.34
$68.64
1週間の範囲:
$62.24
$68.64
52週間の値動き範囲:
$11.39
$68.64
Verona Pharma Plc Adr Stock (VRNA) Company Profile
名前
Verona Pharma Plc Adr
セクター
電話
011-44-0-2032834200
住所
3 MORE LONDON RIVERSIDE, LONDON
VRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
67.96 | 5.56B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | ROTH MKM | Buy |
| 2024-10-03 | 開始されました | Wells Fargo | Overweight |
| 2023-05-22 | 再開されました | Jefferies | Buy |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-08-26 | 開始されました | Piper Sandler | Overweight |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Jefferies | Buy |
| 2020-08-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-18 | 開始されました | BTIG Research | Buy |
すべてを表示
Verona Pharma Plc Adr (VRNA) 最新ニュース
A company insider recently sold 640,264 shares of Verona Pharma Plc ADR [VRNA]. Should You Sale? - Knox Daily
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update - GlobeNewswire Inc.
Verona Pharma stock soars to all-time high of $62.09 - Investing.com India
Verona Pharma stock soars to all-time high of $62.09 By Investing.com - Investing.com South Africa
Canaccord raises Verona Pharma target to $72; maintains buy By Investing.com - Investing.com South Africa
Investor’s Delight: Lithium Americas Corp (NewCo) (LAC) Closes Weak at 2.97, Down -1.98 - The Dwinnex
There is no doubt that Verona Pharma Plc ADR (VRNA) ticks all the boxes. - SETE News
Analyzing Verona Pharma Plc ADR (VRNA) After Recent Trading Activity - Knox Daily
Rumble Inc (RUM)’s Market Momentum: Closing Strong at 12.25, Down -3.92 - The Dwinnex
Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.66, Up/Down -2.12 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: OrganiGram Holdings Inc (OGI) - SETE News
Are Smart Investors Making the Right Decision? Verona Pharma Plc ADR (VRNA) - SETE News
Healthy Upside Potential: Solidion Technology Inc (STI) - SETE News
Stock Surge: XPO Inc (XPO) Closes at 131.50, Marking a 2.24 Increase/Decrease - The Dwinnex
Closing Figures Unveiled: Diageo plc ADR (DEO) Drop -0.84, Closes at 115.95 - The Dwinnex
Market Watch Highlights: Verona Pharma Plc ADR (VRNA) Ends on an Upturn Note at 59.94 - The Dwinnex
Market Momentum Report: Lemonade Inc (LMND)’s Positive Close at 33.99 - The Dwinnex
Stock Market News and Commentary - Barchart
Verona Pharma Keeps Hitting New Highs - Barchart
An Analysis of Knowles Corp (KN)’s Potential Price Growth - Knox Daily
Checking in on Verona Pharma Plc ADR (VRNA) after recent insiders movement - Knox Daily
A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News
Have you been able to find a good deal on Verona Pharma Plc ADR’s shares? - US Post News
The Agilon Health Inc (AGL) had a good session last reading, didn’t it? - US Post News
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Verona Pharma stock target upgraded, retains buy on Q4 results By Investing.com - Investing.com South Africa
Looking For A Top Momentum Pick? Why Valley National Bancorp (NASDAQ: VLY) Is A Great Choice - Stocks Register
Hertz Global Holdings Inc (NASDAQ: HTZ): Overvalued Compared To Others? - Stocks Register
Verona Pharma Plc ADR (VRNA) Outlook: Looking Back For Insights - Stocks Register
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week - Yahoo! Voices
Verona Pharma stock target increased, keeps buy on Q4 sales By Investing.com - Investing.com South Africa
Verona Pharma stock soars to all-time high of $49.05 - Investing.com India
Here are some of BTIG's top picks for the first half of 2025 - Investing.com
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Verona Pharma stock soars to all-time high of $43.76 - Investing.com
Ligand forecasts revenue growth and higher earnings for 2025 - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma CFO sells shares totaling $12,000 - Investing.com India
Verona Pharma's chief medical officer sells $1.18 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $8,000 - Investing.com
Verona Pharma director David Ebsworth buys $88,800 in shares - Investing.com India
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Verona Pharma CEO David Zaccardelli sells $618,657 in shares - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Verona Pharma Plc Adr (VRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):